THE SINGLE BEST STRATEGY TO USE FOR AGO TUMOR

Molecular typing is predicated on molecular genetic screening and is not still routinely accessible. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 may be practical, but a